Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

[1]  R. Giugliano,et al.  The year in non-ST-segment elevation acute coronary syndrome. , 2005, Journal of the American College of Cardiology.

[2]  D. Goff,et al.  Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.

[3]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[4]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[5]  E. Braunwald,et al.  Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. , 2006, European heart journal.

[6]  W. Harris,et al.  Why do omega-3 fatty acids lower serum triglycerides? , 2006, Current opinion in lipidology.

[7]  C. Cannon,et al.  Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. , 2006, Journal of the American College of Cardiology.

[8]  R. Giugliano,et al.  The year in non-ST-segment elevation acute coronary syndromes. , 2006, Journal of the American College of Cardiology.

[9]  Nader Rifai,et al.  Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[10]  E. Braunwald,et al.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[11]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[12]  K. Yano,et al.  Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?: The Honolulu Heart Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  P. Ridker,et al.  Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.

[14]  B. G. Brown.  Can niacin slow the development of atherosclerosis in coronary artery disease patients already taking statins? , 2005, Nature Clinical Practice Cardiovascular Medicine.

[15]  B. Cohen,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[16]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[17]  M. Serio,et al.  Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity , 2004, Journal of endocrinological investigation.

[18]  C. Cannon,et al.  Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation , 2004, Journal of Thrombosis and Thrombolysis.

[19]  M. Linton,et al.  The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy , 2004, Current atherosclerosis reports.

[20]  T. Lam,et al.  Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. , 2004, Annals of epidemiology.

[21]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[22]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[23]  S. Shieh,et al.  Thrombophilia in Patients with Hypertriglyceridemia , 2004, Journal of Thrombosis and Thrombolysis.

[24]  A. Miller.  Some concerns about the future of the practice of cardiovascular medicine , 2003, Clinical cardiology.

[25]  B. Binder,et al.  Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. Larosa.  Understanding risk in hypercholesterolemia , 2003, Clinical cardiology.

[27]  F. Sacks,et al.  Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. , 2002, The American journal of medicine.

[28]  R. Morton,et al.  LDL and HDL enriched in triglyceride promote abnormal cholesterol transport DOI 10.1194/jlr.M100431-JLR200 , 2002, Journal of Lipid Research.

[29]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[30]  MonicaGomaraschi,et al.  Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol , 2002 .

[31]  E. Braunwald,et al.  Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.

[32]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[33]  C. Ballantyne,et al.  The evolving role of high-density lipoprotein in reducing cardiovascular risk. , 2001, Preventive cardiology.

[34]  G. Assmann.  Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. , 2001 .

[35]  R. Morton,et al.  Elevated Triglyceride Content Diminishes the Capacity of High Density Lipoprotein to Deliver Cholesteryl Esters via the Scavenger Receptor Class B Type I (SR-BI)* , 2001, The Journal of Biological Chemistry.

[36]  Jiang He,et al.  Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials , 2000 .

[37]  K. Parhofer,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects* , 2022 .

[38]  M. Miller,et al.  Current perspectives on the management of hypertriglyceridemia. , 2000, American heart journal.

[39]  A. Gotto,et al.  Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. , 1999, Circulation.

[40]  A. Seidler,et al.  Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. , 1998, Journal of the American College of Cardiology.

[41]  J. Buring,et al.  Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. , 1997, Circulation.

[42]  P. Wilson,et al.  Familial lipoprotein disorders and premature coronary artery disease. , 1994, Atherosclerosis.

[43]  A. Hamsten,et al.  Postprandial lipoproteins and progression of coronary atherosclerosis. , 1994, Atherosclerosis.

[44]  E. Schaefer,et al.  Familial lipoprotein disorders and premature coronary artery disease. , 1993, The Medical clinics of North America.

[45]  D. Jacobs,et al.  Plasma triglyceride level and mortality from coronary heart disease. , 1993, The New England journal of medicine.

[46]  L. Tenkanen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study , 1992 .

[47]  Vesa Manninen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.

[48]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[49]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[50]  T. Meade,et al.  HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITY , 1983, The Lancet.

[51]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.